Focus Partners Wealth
RPRX icon

Focus Partners Wealth’s Royalty Pharma RPRX Stock Holding History

Focus Partners Wealth’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.58M Buy
116,250
+15,582
+15% +$682K 0.01% 897
2025
Q4 		$3.89M Buy
+100,668
New +$3.84M ﹤0.01% 1045
2025
Q3 		– Sell
-5,792
Closed -$209K – 2293
2025
Q2 		$209K Sell
5,792
-2,681
-32% -$88.8K ﹤0.01% 1854
2025
Q1 		$264K Buy
+8,473
New +$269K ﹤0.01% 1632

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Focus Partners Wealth's RPRX Position: Q1 2026 in Review

Focus Partners Wealth increased its Royalty Pharma (RPRX) stake by 15% in Q1 2026, buying an estimated $682K and bringing the position to 116,250 shares worth $5.58M. The position accounts for 0.01% of the portfolio, ranked #897.

Focus Partners Wealth first reported a position in RPRX in Q1 2025 and has held it in 4 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Focus Partners Wealth held 116,250 shares of Royalty Pharma worth $5.58M as of Q1 2026.
  • Focus Partners Wealth bought 15,582 Royalty Pharma shares in Q1 2026, an estimated $682K.
  • Royalty Pharma made up 0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #897 holding.
  • Focus Partners Wealth first reported a position in Royalty Pharma in Q1 2025 and has held it in 4 quarters since.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.